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Objective: To compare drug survival of biological therapies in patients with rheumatoid 
arthritis (RA), and analyze the determinants of discontinuation probabilities and switches to 
other biological therapies.
Materials and methods: Consecutive RA patients initiating first biological treatment in one 
rheumatology center between 2006 and 2013 were included. Log-rank test was used to analyze the 
differences between the survival curves of different biological drugs. Cox regression was applied to 
analyze the discontinuation due to inefficacy, the occurrence of adverse events, or to any reasons.
Results: A total of 540 patients were included in the analysis. The most frequently used first-line 
biological treatments were infliximab (N=176, 33%), adalimumab (N=150, 28%), and etanercept 
(N=132, 24%). Discontinuation of first tumor necrosis factor-alpha (TNF-α) treatment was 
observed for 347 (64%) patients, due to inefficacy (n=209, 60%), adverse events (n=103, 30%), 
and other reasons (n=35, 10%). Drug survival rates for TNF-α and non-TNF-α therapies were 
significantly different, and were in favor of non-TNF-α therapies. Every additional number of 
treatment significantly increased the risk of inefficacy by 27% (p<0.001) and of adverse events by 
35% (p=0.002). After the discontinuation of the initial TNF-α treatment, switching to rituximab 
and tocilizumab was associated with significantly longer treatment duration than switching to 
a second TNF-α. The non-TNF-α therapies resulted in significantly longer treatment duration, 
due to both less adverse events and longer maintenance of effectiveness.
Conclusion: Non-TNF-α therapies resulted in significantly longer treatment duration, and lost 
their effectiveness later. Increase in the number of switches significantly increased the risk of 
discontinuation of any biological therapy.
Keywords: rheumatoid arthritis, biologicals, drug survival, switch, registry
Introduction
Rheumatoid arthritis (RA) is a chronic, progressive immune-mediated inflammatory 
disease. The estimated global prevalence of RA is 0.3–1.0% representing one of the most 
prevalent chronic inflammatory diseases. Traditionally, RA was viewed as a joint disease; 
however today, it is considered as a complex systemic condition with extra-articular mani-
festations.1 RA can damage the joints and bones leading to impaired physical functioning 
and work productivity, inducing deterioration of overall emotional and social well-being. 
Moreover, patients are at an increased risk for cardiovascular diseases. RA is associated 
with a large economic burden to both the individual and the society. The estimated RA-
related total annual cost was €45.3 billion in Europe and €41.6 billion in the US in 2006.2
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Disease-modifying antirheumatic drugs (DMARDs) 
play a key role in the management of RA.3 DMARDs are 
classified into two groups: synthetic DMARDs (sDMARDs) 
comprising traditional small-molecular-mass drugs synthe-
sized chemically; and biological DMARDs (bDMARDs), a 
group of drugs with complex protein molecules produced 
through genetic engineering. The first bDMARD was reg-
istered in the early 2000s for the treatment of RA patients 
with active disease, and currently, eight biological substances 
are available with indication for RA. Biologicals revolution-
ized the treatment of RA as it was proved by clinical trials 
that bDMARDs are effective in patients not responding to 
sDMARDs, with a mean response rate of 60–70%.4 The 
treatment goal in RA is to achieve and maintain remission or 
at least low disease activity. Therefore, in RA management, 
patients have to be regularly followed, and those without 
or with incomplete response and also patients with loss of 
response should either have an increased dose or switch to 
a subsequent bDMARD.3 Use of biologicals has expanded 
in the past years, and registry data from various countries 
and jurisdictions provide real-world evidences on the clini-
cal effectiveness and safety of bDMARDs and also on drug 
utilization patterns.5
Survival of biological therapies in RA has been analyzed 
in the literature based on randomized controlled trials, obser-
vational studies, and registries.6–9 Although international 
clinical guidelines provide updated evidences on bDMARDs 
use, there are remarkable intercountry differences in treat-
ment practices and in access to bDMARD therapies.3,10 These 
differences can have important effects on therapy durations. 
The duration of therapies can be influenced by the number 
of financed biological therapies, regulations related to the 
initiation and continuation of and switches between therapies, 
administrative requirements, and infrastructural background. 
Other influencing factors can be the common clinical prac-
tice, clinical characteristics of the patients (duration of ill-
ness, comorbidities, other medications, distance from home 
to the treatment center), and financial deficits of the funder.11 
Demographic and cultural differences can also influence the 
survival of a drug therapy.12
We analyzed the survival of biological therapies and its 
influencing factors in Hungary. Financing of biological thera-
pies in Hungary started later, and conditions for beginning 
a biological therapy are more restrictive than in many other 
(primarily Western European) countries.13 Such restrictive-
ness is present in most of the Central and Eastern European 
(CEE) countries, although to varying extent.10,14–16 Biological 
register and studies based on that exist only in the Czech 
Republic; thus, little is known about the survival of biological 
therapies and its influencing factors in this setting.17,18 Further 
knowledge could help decision makers improve regulations 
of bDMARD therapies and clinicians improve their therapy 
practices. Moreover, given the high costs of bDMARDs, 
results of economic analyses based on local data play a sig-
nificant role in the reimbursement decisions of these drugs. 
This aspect is especially relevant in budget impact analyses 
(BIAs) in which the financing consequences of the decision 
are estimated for a specific health care system. The number 
of eligible patients for the treatment and the estimated drug 
uptake highly depend on the rate of entering and leaving 
patients in the specific setting.19 The significance of BIAs 
in RA will presumably further increase as the first biosimi-
lar versions of the bDMARDs have been registered since 
2013 and other biosimilars are in pipeline. Biosimilars, by 
definition, have similar efficacy and safety as their origina-
tor bDMARD but are of lower price; hence, their potential 
impact on health care budgets is a hot issue.20,21 Insights into 
current bDMARD use and determinants of drug survivals 
in different jurisdictions are, on the one hand, key elements 
for reliable BIA estimates in a country. On the other hand, 
revealing similarities and differences in bDMARD survivals 
between countries can contribute to a better understanding of 
economic data transferability issues at the international level.
The objective of the study is, therefore, to compare dura-
tion of treatment with bDMARDs of patients with RA and to 
analyze the factors which influence the risk of discontinuation 
of therapy due to inefficacy, the occurrence of adverse events, 
or either of these reasons. This study fills a gap being the first 
analysis in Hungary and in the CEE region, and results are 
discussed in the light of results from other countries.
Materials and methods
Patients and study design
This is a retrospective analysis of patient records on the per-
sistence of biological therapies used to treat RA. The study 
was carried out in Hungary at the Division of Rheumatol-
ogy, Institute of Medicine, University of Debrecen Medical 
and Health Sciences Center. The study was approved by the 
Institutional Review Board of the University of Debrecen. 
Patient consent to review medical records was not required 
for the study. The data cover therapies from 2006 to the end 
of February 2013.
All patients diagnosed with RA, who went to the Divi-
sion of Rheumatology, Institute of Medicine, University of 
Debrecen Medical and Health Sciences Center, and who 
were given at least one dose of biological therapy during the 
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study period, were included. This is an observational study, 
and hence, patients were not recruited as participants of a 
clinical trial. The observation period started from the day of 
first administration until failure or until the closing date of 
the observation period.
Biological treatment criteria in hungary
The National Health Insurance Fund Administration (NHIFA) 
covers the whole population in Hungary. Due to high cost of 
bDMARDs, biological treatment of RA patients in clinical 
practice is driven mainly by financial guidelines of NHIFA. At 
the time of the study period, seven different bDMARDs were 
available and reimbursed in Hungary for the treatment of RA 
(100% of drug price covered): Humira (adalimumab [ADA]; 
AbbVie Inc., North Chicago, IL, USA), Cimzia (certolizumab 
pegol [CTZ]; UCB Pharma, Brusselsm, Belgium), Enbrel 
(etanercept [ETA]; Pfizer, New York, NY, USA), Simponi (goli-
mumab [GOL]; Janssen Biologics, Leiden, The Netherlands), 
Remicade (infliximab [INF]; Janssen Biologics, Leiden, The 
Netherlands), Mabthera (rituximab [RTX]; Basel, Switzerland), 
and Ro-Actemra (tocilizumab [TCZ] Basel, Switzerland). Of 
note, ADA, ETA, and INF are reimbursed since 2006 and RTX 
since 2007, while CTZ, GOL, and TCZ since 2010, for the treat-
ment of RA in Hungary. Twenty-two hospital-based rheumatol-
ogy centers were entitled to provide bDMARD treatment in RA.
Disease activity is measured by a composite index in 
RA, the so-called Disease Activity Score considering 28 
joint count (DAS28), comprising the number of tender and 
swollen joints, patient’s global assessment of the disease on 
a visual analog scale, and a laboratory test on inflammation 
(erythrocyte sedimentation rate or C-reactive protein). In RA 
care, assessment of DAS28 by rheumatologists is required 
every 3 months regardless of the treatments applied in order 
to follow the course of the disease and to control tightly the 
symptoms with therapy adjustments. Specific cutoff points 
are used to determine mild, moderate, and high disease activ-
ity, and the change in DAS28 is also used for the evaluation 
of the treatment effects.22
At the time of the study, the financial regulation allowed 
the initiation of biological treatment only for RA patients 
with high disease activity (DAS28 higher than 5.1) despite 
adequate treatment with combination of two sDMARDs, 
including methotrexate, for at least 3 months. In first line, 
tumor necrosis factor-alpha (TNF-α) inhibitors (anti-TNF-α: 
ADA, CTZ, ETA, GOL, INF) or interleukin-6 receptor 
inhibitor (TCZ) could be applied. In some specific cases, 
RTX could be used as first-line bDMARD under individual 
license. Patients had to be assessed for effectiveness every 
3 months, and a decrease of at least 1.2 point in DAS28 3 
months after the initiation of the treatment was required for 
the continuation of the biological drug. In case of inefficacy, 
switch to another anti-TNF-α, TCZ, or RTX had to be con-
sidered. Switch between bDMARDs was allowed in case of 
intolerance as well.
Rheumatologists providing biological treatment were 
commissioned to assess and register treatment intolerance 
following the regular rules of the profession and the regula-
tion of the European Medicines Agency on drug contraindi-
cations. Adverse events leading to stop of the therapy could 
vary from local allergic reaction of the skin at the injection 
site to life-threatening anaphylactic shock, but also infections, 
development of oncological diseases, or gravidity could result 
in discontinuation of the therapy.
There was no further rule for discontinuation of bDMARD 
treatment if the patient fulfilled the effectiveness criteria (i.e., 
continuous bDMARD treatment was allowed). Dose increase 
due to inefficacy was not allowed (not reimbursed) in case of 
any bDMARD. There was no limit in the number of different 
bDMARDs that could be applied in the course of the disease 
(i.e., no limit in the number of switches).13
Disease activity (DAS28) had to be assessed before the 
initiation of any new bDMARD (regardless of being first or 
subsequent bDMARD treatment), and the same check-ups 
and assessments were required as for the first bDMARD.
statistical analysis
Log-rank test for equality of drug survival (hereinafter sur-
vival) functions was used to compare the average survival 
times of biological drugs. In the context of this paper, survival 
time means the time period between the first and last admin-
istration of a given biological during the observation period, 
or from the first administration until the time when treatment 
failure for any reasons was declared (discontinuation of the 
therapy). TNF-α and non-TNF-α therapies were separately 
compared for discontinuation due to loss of efficacy or due 
to the occurrence of adverse events.
Cox multivariate regression models were used to analyze 
what factors influence the risk of discontinuation of different 
biological therapies. Standard errors were clustered at the 
individual level. Three different models were built to analyze 
the hazard ratios (HRs) of the discontinuation due to 1) loss 
of efficacy, 2) occurrence of adverse events, or 3) any reasons. 
The following variables were used as independent variables in 
the analysis: number of previous biological treatments, rheu-
matoid factor (positive/negative), disease duration (years), 
anti-cyclic citrullinated peptide antibodies (positive/negative), 
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corticosteroid use (yes/no), age (at the time of initiation of 
first bDMARD) and gender of the patient, and if there was a 
gap longer than a month since the previous treatment. Dummy 
variables were used to indicate the study drugs (CTZ was used 
as the base category). The indicator of concomitant sDMARD 
use was set to one for those two biologicals, the use of which 
is mandatory by protocol (INF and RTX).
The data were analyzed using the statistical program Stata 
13.1 (StataCorp, College Station, TX, USA).
Results
Descriptive statistics
As much as 540 RA patients were included in the analysis. 
Patient characteristics are presented in Table 1.
Most of the patients were treated by INF (33%), ADA 
(28%), and ETA (24%) as first-line therapy. The median 
survival time on these drugs was 519, 511, and 546 days, 
respectively. There were data on 57 patients who started with 
a less frequent TNF-α therapy (CTZ: 34 GOL: 23) and 25 
patients who started with a non-TNF-α therapy. Discontinu-
ation of first TNF-α treatment was observed for 347 (64%) 
patients, due to inefficacy (n=209, 60%), adverse events 
(n=103, 30%), or other reasons (n=35, 10%). Altogether, 322 
patients (60%) switched to a second biological treatment. 
The most frequently applied second-line treatment was RTX 
(25%), with a median survival time of 1302 days. The next 
most used second-line treatments were INF (21%), ETA 
(15%), and ADA (14%). The median survival time on these 
drugs (as second-line bDMARD treatment) was 386, 398, 
and 287 days, respectively. As much as 157 patients changed 
to a third biological treatment, 57 patients to fourth, 22 to 
fifth, eight to sixth, and two to seventh treatment.
The average number of biological treatments per patient 
was 1.9 (median 2, min 1, max 7). The average number of bio-
logical treatments per patient with at least two treatments was 
2.7. Altogether, 1108 periods of treatments were included in 
the data. Each treatment period corresponded to one biologi-
cal treatment. There were five overlapping treatment periods 
in the data, partly due to data input error; these observations 
were not included in the Cox hazard model. Forty-one percent 
of the treatment observations were censored.
As much as 362 gaps (>0 day) were observed between two 
treatments, on an average of 91 (standard deviation 206) days. 
A total of 134 gaps lasted longer than 30 days, which were 
observed among 113 patients. The reasons of discontinuation 
before gaps longer than 30 days were inefficacy in 53 cases 
(39.6%) and adverse events in 55 cases (41.0%).
log-rank test
We carried out the comparison of the survivals, separately 
for discontinuation due to inefficacy and to adverse events. 
Statistically significant differences were found in the time 
until a change in treatment due to loss of efficacy, and the 
results of the log-rank test showed that the survival functions 
for the different biologicals were statistically significantly dif-
ferent (Chi2=51.7, p=0.000). The best survivals were observed 
for the non-TNF-α agents, RTX, and TCZ (Kaplan–Meier 
survival estimates are presented in Figure 1). When we com-
pared the survival functions of the TNF-α and non-TNF-α 
treatments, we found that the two survival curves were also 
significantly different (Chi2=40.6, p=0.000), with better 
survivals for the non-TNF-α therapies.
We found no significant differences among the biologicals 
in the time until a change in treatment due to the occurrence 
of adverse events (Chi2=8.4, p=0.209). Similarly, the differ-
ence between the survival on TNF-α and non-TNF-α was 
not significant (Chi2=3.8, p=0.051).
Cox regression
In the first model, where we analyzed the discontinuation 
due to inefficacy, a gap of more than 30 days and RTX were 
found to be significant determinants at 5% significance level. 
Table 1 Descriptive statistics at the patient level or treatment 
period level
Characteristics Total sample (N=540, 
treatment periods=1108)
age, mean (sD) 53.6 (12.8)
Woman, n (%) 456 (84.4)
Disease duration (in years) at first therapy 
(n=525), mean (sD)
12.1 (9.2)
Rheumatoid factor (n=521 patients)
negative, n (%) 194 (37.2)
Positive, n (%) 327 (62.8)
anti-CCP (n=524 patients)
negative, n (%) 183 (35.0)
Positive, n (%) 341 (65.0)
Corticosteroid use (n=1099 treatment periods)
no, n (%) 674 (61.3)
Yes, n (%) 425 (38.7)
sDMaRD (n=1105 treatment periods)
no, n (%) 230 (20.8)
Yes, n (%) 875 (79.2)
First bDMaRD (n=540)
TnF-α, n (%) 515 (92.6)
non-TnF-α, n (%) 25 (7.4)
gap more than 30 days since last bDMaRD therapy (n=1108 treatment 
periods)
No (including first therapy), n (%) 974 (87.9)
Yes, n (%) 134 (12.1)
Abbreviations: bDMaRD, biological disease-modifying antirheumatic drug; CCP, 
cyclic citrullinated peptide; sD, standard deviation; sDMaRD, synthetic disease-
modifying antirheumatic drug; TnF-α, tumor necrosis factor-alpha.
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Age was found to be significant at 10% significance level 
(Table 2). A gap of more than 30 days decreased the risk of 
inefficacy by 40% (p=0.009). Every change of treatment sig-
nificantly increased the risk of inefficacy by 27% (p=0.000). 
One-year increase in the patients’ age increased the risk of 
discontinuation due to inefficacy by 0.7% (p=0.066). Disease 
duration at the time of first bDMARD administration was 
insignificant. Compared to CTZ, RTX had 55% lower HR 
(p=0.036). There were no significant differences between 
other biologicals compared to CTZ.
In the second model, where we analyzed the discontinu-
ation due to the occurrence of adverse events, we found that 
other factors influenced the risk than in the previous model 
(Table 2). Every change of treatment was estimated to 
increase the risk of adverse events by 35% (p=0.002). The 
disease duration was also significant in this model, but not 
in the model of inefficacy: one-year increase of the disease 
duration increased the risk of discontinuation due to adverse 
events by 1.5% (p=0.037). The HR was 38% lower for men 
than for women (p=0.036). If the patient was treated with con-
comitant sDMARD, the risk of discontinuation of bDMARD 
due to adverse events was lower by 41% (p=0.014).
When we did not distinguish between the reason of the 
discontinuation of the therapy (Table 2), we found that HRs 
were significantly different between men and women – men 
had 23% lower HR (p=0.037). The risk of discontinuation 
of therapy increased with age – one additional year of age 
increased the HR by 0.7% (p=0.015). A gap of more than 30 
days decreased the discontinuation risk by 27% (p=0.009). 
The use of concomitant sDMARDs decreased the risk of 
discontinuation by 29% (p=0.001). Regarding the differences 
between biologicals, RTX and TCZ had 57% and 55% lower 
HRs compared to CTZ (p=0.001 and p=0.009, respectively), 
while the difference between CTZ and the other study drugs 
was not statistically significant. An additional number of 
treatment was estimated to increase the risk of discontinua-
tion by 26% (p=0.000).
Figure 2 shows that while the non-TNF-α therapies were 
better in terms of survival, for both types of drugs, the risk 
of discontinuation increased with the number of different 
biological treatments.
Discussion
We applied survival analysis to examine the factors which 
influence the differences in the average time of biological treat-
ments in patients with RA. In the analysis, we distinguished 
three reasons for discontinuation of bDMARD therapy: 
1) discontinuation due to inefficacy, 2) discontinuation due 
to adverse events, and 3) discontinuation due to any reason.
The non-TNF-α therapies resulted in significantly longer 
treatment duration, and lost their effectiveness later. Also, the 
risk of discontinuation due to adverse events was significantly 
lower for non-TNF-α therapies.
We found differences regarding which factors influence 
the discontinuation of therapy due to inefficacy and due to 
the occurrence of adverse events. The number of switches 
significantly increased the risk of discontinuation of therapy 
due to inefficacy, adverse events, and any reason. Patients’ 
age increased the risk of discontinuation due to inefficacy, 
but only at the 10% significance level.
Kaplan–Meier survival estimates
Analysis time (days)
CTZ
ADA
INF
GOL
ETA
RTX
TCZ
0
1.00
0.75
0.50
0.25
0.00
500 1000 1500 2000 2500
Figure 1 Survival times – discontinuation due to inefficacy by drug.
Abbreviations: ADA, adalimumab; CTZ, certolizumab pegol; ETA, etanercept; GOL, golimumab; INF, infliximab; RTX, rituximab; TCZ, tocilizumab.
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Table 2 Cox regression – hazard ratios of discontinuation due to inefficacy, to adverse events, and to any reason
Number of subjects=502
Number of observed treatment period=1026
Standard error adjusted for individual clusters
Variables Discontinuation due  
to inefficacy
Discontinuation due to 
adverse events
Discontinuation due to  
any reason
HR Standard 
error
p-Value HR Standard 
error
p-Value HR Standard 
error
p-Value
Order of treatment 1.272 0.087 <0.001 1.349 0.128 0.002 1.260 0.070 <0.001
age 1.007 0.004 0.066 1.006 0.006 0.361 1.007 0.003 0.015
Male 0.898 0.153 0.528 0.620 0.142 0.036 0.769 0.097 0.037
RF 1.048 0.138 0.725 0.900 0.154 0.536 1.003 0.094 0.973
anti-CCP 0.878 0.115 0.317 0.914 0.158 0.601 0.898 0.085 0.257
steroid 0.931 0.108 0.537 1.112 0.183 0.519 0.985 0.084 0.856
sDMaRD 0.818 0.121 0.175 0.585 0.127 0.014 0.707 0.077 0.001
Years of disease 1.000 0.006 0.972 1.015 0.007 0.037 1.006 0.004 0.109
gap above 30 days 0.604 0.116 0.009 0.829 0.207 0.454 0.730 0.088 0.009
Biological
ETa 1.220 0.444 0.584 0.630 0.261 0.265 0.767 0.181 0.26
aDa 1.772 0.633 0.109 0.554 0.228 0.152 0.976 0.225 0.916
RTX 0.450 0.172 0.036 0.505 0.234 0.139 0.434 0.108 0.001
inF 1.552 0.565 0.227 1.040 0.416 0.923 1.088 0.256 0.72
TCZ 0.597 0.257 0.23 0.474 0.246 0.151 0.455 0.137 0.009
gOl 0.942 0.392 0.886 0.918 0.426 0.854 0.746 0.209 0.295
Note: Bold: significant at 0.05 level.
Abbreviations: ADA, adalimumab; CCP, cyclic citrullinated peptide; ETA, etanercept; GOL, golimumab; HR, hazard ratio; INF, infliximab; RF, rheumatoid factor; RTX, 
rituximab; sDMaRD, synthetic disease-modifying antirheumatic drug; TCZ, tocilizumab.
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Figure 2 Cox-regression-predicted survival times – discontinuation due to any reason, by number of treatment, and TnF-α.
Notes: Fixed variables and their values: rheumatoid factor=0, anti-cyclic citrullinated peptide antibodies=0, steroid=0, sDMaRD=1, disease years=13, and gap longer than 
a month=0.
Abbreviations: sDMaRD, synthetic disease-modifying antirheumatic drug; TnF-α, tumor necrosis factor-alpha.
Gaps in TNF blocker therapy are common practice.23–27 
In our study sample, a gap between two bDMARD treat-
ments significantly decreased the risk of discontinuation 
due to inefficacy. The significant effect of gap was robust to 
excluding the first treatment periods from the sample. The 
magnitude of the estimated effect of a previous gap was 
similar among the TNF-α and non-TNF-α therapies, although 
insignificant in case of non-TNF-α therapies, due to limited 
sample size. Analysis by individual bDMARDs could have 
been informative but was limited by sample size.28,29 We 
found some evidence that a gap is more likely to decrease 
the risk of discontinuation due to inefficacy if the previous 
treatment ended due to inefficacy. Possible explanation for the 
beneficial effect of a gap between treatments is that a treat-
ment after a long gap acts as if a first treatment, as disease 
severity might have increased during the gap. This increase 
could have exceeded the initial DAS28 score, providing more 
space for the following (second, third, etc.) bDMARD to 
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achieve a minimum 1.2-point decrease in DAS28. Disease 
flares and the efficiency of treatment after restart are in line 
with Huizinga et al and Smolen and Aletaha.30,31 We encour-
age further studies to include DAS28 scores in the analysis 
of gap effects.
When we did not distinguish between the reasons for 
discontinuation, the number of switches, age of the patient, 
gender (higher risk for women), concomitant sDMARD use, 
and gap in the therapy were found to be significant determi-
nants of the risk of discontinuation.
Souto et al conducted a meta-analysis based on data from 
registries and health care databases to assess discontinuation 
of biological therapies in RA.32 They found that ETA and 
the concomitant use of sDMARDs decreased, while disease 
duration and female gender increased, the risk of discon-
tinuation. While our findings support the results related to 
sDMARD use, disease duration, and gender, we extend the 
analysis with comparing treatment durations of TNF-α and 
non-TNF-α therapies and estimating the effect of number of 
switches on treatment duration. The rate of switching from 
the first biological to a second bDMARD was 60%, while 
Gomez-Reino and Carmona documented a much lower rate, 
around 10% of switches.33
We found that the order of RA treatment (in terms of 
the number of applied bDMARDs before the observed 
bDMARD) decreased survival, which is in line with findings 
by Gomez-Reino and Carmona, Hyrich et al, and Martínez-
Santana et al.33–35 However, our study provides a more exten-
sive picture as we analyzed more drugs, including non-TNF-α 
therapies, and over a longer time horizon.
Buch et al in their review highlighted that switching to 
another TNF blocker may provide benefit, but available evi-
dences are limited and registry data demonstrate declining 
survival pattern.36 Our result that switching to a non-TNF-α 
therapy is associated with significantly longer treatment 
duration than switching to a second TNF-α is in line with 
the results of Emery et al who found that switching to RTX is 
associated with significantly improved clinical effectiveness 
compared with switching to a second TNF-α.37
The result that treatment durations are higher among 
non-TNF-α therapies corresponds to the results of Hishitani 
et al.38 Like Koutsianas et al, we did not find significant dif-
ference in survival between non-TNF-α therapies applied 
after the failure of a TNF-α therapy.39
Limitations
We had to face some data limitations when conducting this 
study. The missing observations in some of the regressors 
(as indicated in Table 1) are not likely to influence the con-
clusions. We did not have information on comorbidities and 
coexisting therapies. The sDMARD indicator is subject to 
measurement error.
Our data are based on the clinical practice of one of the 
22 rheumatology centers that were entitled to apply biological 
treatment in RA, and therefore, generalizability of the results 
to the national level is limited. However, the total number of 
RA patients on biological treatment in September 2013 was 
4565 in Hungary; hence, this one center represents about 9% 
of this patient population (we observed 397 patients in year 
2013).14 The distribution of patients across bDMARDs at the 
national level (data from September 2013) compared to the 
respective rates throughout years 2006–2013 in this center 
was as follows: ADA 20% vs 19%, CTZ 16% vs 5%, ETA 
20% vs 18%, GOL 10% vs 8%, INF 7% vs 24%, RTX 9% 
vs 16%, and TCZ 18% vs 9%; this reflects some differences 
from the national distribution.
Gaps between biological treatments can be influenced 
by the treatment schedule of the different drugs, regulation 
on check-ups, drug supply, patients’ adherence, and fur-
ther factors in a specific country or rheumatology center. 
Moreover, the reasons and the exact circumstances of the 
discontinuation can also have an impact on the gap. For 
instance, early discontinuation of a therapy due to allergic 
reaction (without providing a full dose) can allow a switch 
earlier than the prescribed interval between two full doses. 
In our study, we considered a gap of 4 weeks which might 
be too short for treatments with long retreatment periods 
(e.g., RTX 6 months) and too long for weekly treatments 
(ETA). Given the retrospective character of our study, we 
had to rely on the best available data and could not con-
sider all gap-related details in our analyses. We believe 
that the 4-week gap applied is a reasonable approach for 
the biologicals involved in this analysis. However, we 
encourage further prospective studies to focus more on 
the gaps and related context in order to confirm, refine, or 
maybe disprove our findings about the impact of treatment 
gaps.
Conclusion
Analyzing biological therapies in patients with RA, non-
TNF-α therapies resulted in significantly longer treatment 
duration, and lost their effectiveness later. Also, the risk of 
discontinuation due to adverse events was significantly lower 
for non-TNF-α therapies. The number of switches signifi-
cantly increased the risk of discontinuation of therapy due 
to inefficacy or adverse events.
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